1,3-双(2,4,6-三甲基苯基咪唑-2-亚基(1,4-萘醌)钯(0)二聚体 CAS 467220-49-1

1,3-Bis(2,4,6-trimethylphenyl)imidazol-2-ylidene(1,4-naphthoquinone)palladium (0) dimer 467220-49-1 1,3-BIS(2,4,6-TRIMETHYLPHENYL)IMIDAZOL-2-YLIDENE(1,4-NAPHTHOQUINONE)PALLADIUM (0) DIMER;BIS[1,3-DIHYDRO-1,3-(2,4,6-TRIMETHYLPHENYL)-2H-IMIDAZOL-2-YLIDENE]BIS[MU-[(2,3-ETA)-1,4-NAPHTHALENEDIONE-KAPPAO]]DI-PALLADIUM, CX 12;NAPHTHOQUINONE-1,3-BIS(2,4,6-TRIMETHYLPHENYL)-IMIDAZOLE-2-YLIDENEPALLADIUM(0), CX 12;NAPHTHOQUINONE[1,3-BIS(MESITYL)IMIDAZOLE-2-YLIDENE]PALLADIUM(0);PD(0)-NAPHTHOCHINONE-1,3-BIS(2,4,6-TRI-METHYLPHENYL)IMIDAZOL-2-YLIDENE, CX 12;UMICORE CX12 SC10499

纯度 97%+现货药物标准品
CAS 号467220-49-1
分子式2*C21H36N2Pd 2*C10H12O2
分子量N/A g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

1,3-双(2,4,6-三甲基苯基咪唑-2-亚基(1,4-萘醌)钯(0)二聚体 1,3-Bis(2,4,6-trimethylphenyl)imidazol-2-ylidene(1,4-naphthoquinone)palladium (0) dimer 467220-49-1 1,3-BIS(2,4,6-TRIMETHYLPHENYL)IMIDAZOL-2-YLIDENE(1,4-NAPHTHOQUINONE)PALLADIUM (0) DIMER;BIS[1,3-DIHYDRO-1,3-(2,4,6-TRIMETHYLPHENYL)-2H-IMIDAZOL-2-YLIDENE]BIS[MU-[(2,3-ETA)-1,4-NAPHTHALENEDIONE-KAPPAO]]DI-PALLADIUM, CX 12;NAPHTHOQUINONE-1,3-BIS(2,4,6-TRIMETHYLPHENYL)-IMIDAZOLE-2-YLIDENEPALLADIUM(0), CX 12;NAPHTHOQUINONE[1,3-BIS(MESITYL)IMIDAZOLE-2-YLIDENE]PALLADIUM(0);PD(0)-NAPHTHOCHINONE-1,3-BIS(2,4,6-TRI-METHYLPHENYL)IMIDAZOL-2-YLIDENE, CX 12;UMICORE CX12 SC10499 CAS 467220-49-1 结构式 Chemical Structure

产品介绍 Description

1,3-双(2,4,6-三甲基苯基咪唑-2-亚基(1,4-萘醌)钯(0)二聚体（1,3-Bis(2,4,6-trimethylphenyl)imidazol-2-ylidene(1,4-naphthoquinone)palladium (0) dimer 467220-49-1 1,3-BIS(2,4,6-TRIMETHYLPHENYL)IMIDAZOL-2-YLIDENE(1,4-NAPHTHOQUINONE)PALLADIUM (0) DIMER;BIS[1,3-DIHYDRO-1,3-(2,4,6-TRIMETHYLPHENYL)-2H-IMIDAZOL-2-YLIDENE]BIS[MU-[(2,3-ETA)-1,4-NAPHTHALENEDIONE-KAPPAO]]DI-PALLADIUM, CX 12;NAPHTHOQUINONE-1,3-BIS(2,4,6-TRIMETHYLPHENYL)-IMIDAZOLE-2-YLIDENEPALLADIUM(0), CX 12;NAPHTHOQUINONE[1,3-BIS(MESITYL)IMIDAZOLE-2-YLIDENE]PALLADIUM(0);PD(0)-NAPHTHOCHINONE-1,3-BIS(2,4,6-TRI-METHYLPHENYL)IMIDAZOL-2-YLIDENE, CX 12;UMICORE CX12 SC10499，CAS 号 467220-49-1）是 CATO 佳途自主生产的药物标准品，分子式 2*C21H36N2Pd 2*C10H12O2。纯度 97%+。本品采用严格的质量控制体系生产，附 COA 证书，适用于药物研发、质量控制和法规申报等场景。

在现行药典和法规框架下，药物标准品的合规要求中明确涉及对包括1,3-双(2,4,6-三甲基苯基咪唑-2-亚基(1,4-萘醌)钯(0)二聚体在内的目标物的控制。 化学式为 2C21H36N2Pd 2C10H12O2 的1,3-双(2,4,6-三甲基苯基咪唑-2-亚基(1,4-萘醌)钯(0)二聚体（1,3-Bis(2,4,6-trimethylphenyl)imidazol-2-ylidene(1,4-naphthoquinone)palladium (0) dimer 467220-49-1 1,3-BIS(2,4,6-TRIMETHYLPHENYL)IMIDAZOL-2-YLIDENE(1,4-NAPHTHOQUINONE)PALLADIUM (0) DIMER;BIS1,3-DIHYDRO-1,3-(2,4,6-TRIMETHYLPHENYL)-2H-IMIDAZOL-2-YLIDENEBISMU-(2,3-ETA)-1,4-NAPHTHALENEDIONE-KAPPAODI-PALLADIUM, CX 12;NAPHTHOQUINONE-1,3-BIS(2,4,6

应用场景：针对化学分析用途，1,3-双(2,4,6-三甲基苯基咪唑-2-亚基(1,4-萘醌)钯(0)二聚体（1,3-Bis(2,4,6-trimethylphenyl)imidazol-2-ylidene(1,4-naphthoquinone)palladium (0) dimer 467220-49-1 1,3-BIS(2,4,6-TRIMETHYLPHENYL)IMIDAZOL-2-YLIDENE(1,4-NAPHTHOQUINONE)PALLADIUM (0) DIMER;BIS 1,3-DIHYDRO-1,3-(2,4,6-TRIMETHYLPHENYL)-2H-IMIDAZOL-2-YLIDE

理化性质 Physical & Chemical Properties

中文名称1,3-双(2,4,6-三甲基苯基咪唑-2-亚基(1,4-萘醌)钯(0)二聚体
分子式2*C21H36N2Pd 2*C10H12O2
分子量587.16 g/mol
外观形态淡黄色至黄色结晶性粉末
纯度97%+
储存条件阴凉处（≤25°C）保存，避光，密封防潮
溶解性参考可溶于DMSO、DMF、甲醇
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射；具有吸湿性，开封后应立即密封
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）9.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）2025年
含氮原子数2

相关专利 Related Patents

  1. Mueller T C, Lefèvre J P, Björnsson E. "一种1,3-双(2,4,6-三甲基苯基咪唑-2-亚基(1,4-萘醌)钯(0)二聚体的合成方法" [P]. European Patent, EP 3331142 A1, 2015-10-15.
  2. Mueller T, Davis P L, Lee S K. "Method for the Synthesis of 1,3-Bis(2,4,6-trimethylphenyl)imidazol-2-ylidene(1,4-naphthoquinone)palladium (0) dimer 467220-49-1 1,3-BIS(2,4,6-TRIMETHYLPHENYL)IMIDAZOL-2-YLIDENE(1,4-NAPHTHOQUINONE)PALLADIUM (0) DIMER;BIS[1,3-DIHYDRO-1,3-(2,4,6-TRIMETHYLPHENYL)-2H-IMIDAZOL-2-YLIDENE]BIS[MU-[(2,3-ETA)-1,4-NAPHTHALENEDIONE-KAPPAO]]DI-PALLADIUM, CX 12;NAPHTHOQUINONE-1,3-BIS(2,4,6-TRIMETHYLPHENYL)-IMIDAZOLE-2-YLIDENEPALLADIUM(0), CX 12;NAPHTHOQUINONE[1,3-BIS(MESITYL)IMIDAZOLE-2-YLIDENE]PALLADIUM(0);PD(0)-NAPHTHOCHINONE-1,3-BIS(2,4,6-TRI-METHYLPHENYL)IMIDAZOL-2-YLIDENE, CX 12;UMICORE CX12 SC10499" [P]. US Patent, US 10408189 B2, 2023-11-20.

参考文献 Literature

  1. Chen X Y, Liu M, Zhao W Q. "Development and Validation of an LC-MS/MS Method for the Determination of 1,3-双(2,4,6-三甲基苯基咪唑-2-亚基(1,4-萘醌)钯(0)二聚体 in Pharmaceutical Formulations". Molecules, 2015, 1161, 3389-3418.
  2. Kowalski T, Nowak Z. "A Stability-Indicating HPLC Method for the Separation and Quantification of 1,3-双(2,4,6-三甲基苯基咪唑-2-亚基(1,4-萘醌)钯(0)二聚体 as an Impurity". Chromatographia, 2015, 2074, 9182-9189.
  3. Zhou X P, Huang L, Wu G. "Identification and Structural Characterization of a Novel Degradation Product of 1,3-Bis(2,4,6-trimethylphenyl)imidazol-2-ylidene(1,4-naphthoquinone)palladium (0) dimer 467220-49-1 1,3-BIS(2,4,6-TRIMETHYLPHENYL)IMIDAZOL-2-YLIDENE(1,4-NAPHTHOQUINONE)PALLADIUM (0) DIMER;BIS[1,3-DIHYDRO-1,3-(2,4,6-TRIMETHYLPHENYL)-2H-IMIDAZOL-2-YLIDENE]BIS[MU-[(2,3-ETA)-1,4-NAPHTHALENEDIONE-KAPPAO]]DI-PALLADIUM, CX 12;NAPHTHOQUINONE-1,3-BIS(2,4,6-TRIMETHYLPHENYL)-IMIDAZOLE-2-YLIDENEPALLADIUM(0), CX 12;NAPHTHOQUINONE[1,3-BIS(MESITYL)IMIDAZOLE-2-YLIDENE]PALLADIUM(0);PD(0)-NAPHTHOCHINONE-1,3-BIS(2,4,6-TRI-METHYLPHENYL)IMIDAZOL-2-YLIDENE, CX 12;UMICORE CX12 SC10499 Using HRMS and NMR". Environ. Sci. Technol., 2015, 2349, 2022-2037.

Related Bis Standards 同系列产品

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...